Loading the security overview…
Where the tokens are
First the companies classified under the same themes, most themes in common first; then the ones investors most often look at alongside CAI. A peer with a tokenized version links to its own page, where every issuer that wraps it is listed.
| Company | Shared themes | Market cap | P/E | P/S | EV/EBITDA | ROE | F-Score | Altman zone |
|---|---|---|---|---|---|---|---|---|
| — | $8.01B | 76.2 | 8.1 | 44.3 | 17.8% | 5/9 | safe | |
| Cancer Diagnostics & BiomarkersPrecision Medicine Platforms | $23.45B | — | 19.8 | -55.4 | 203.5% | 3/9 | safe | |
| AI-Powered Analytics & Decision SystemsPrecision Medicine Platforms | $13.89B | — | 9.7 | -114.0 | −57.2% | 3/9 | safe | |
| Cancer Diagnostics & BiomarkersPrecision Medicine Platforms | $4.37B | — | 14.2 | -212.6 | −44.7% | 5/9 | safe | |
| Cancer Diagnostics & BiomarkersPrecision Medicine Platforms | $1.08B | — | 3.0 | -62.1 | −4.1% | 4/9 | safe | |
| AI-Powered Analytics & Decision SystemsPrecision Medicine Platforms | $706.56M | — | — | — | — | 2/9 | distress | |
| Cancer Diagnostics & BiomarkersPrecision Medicine Platforms | $288.36M | — | 2.8 | -20.3 | −303.6% | 4/9 | distress | |
| AI-Powered Analytics & Decision Systems | $456.68B | 151.4 | 74.2 | 170.8 | 30.9% | 7/9 | safe | |
| AI-Powered Analytics & Decision Systems | $272.46B | 4660.6 | 50.5 | 1258.2 | 1.1% | 3/9 | safe | |
| Precision Medicine Platforms | $244.58B | 110.1 | 10.2 | 48.8 | 16.4% | 8/9 | safe | |
| Precision Medicine Platforms | $241.26B | 34.6 | 5.2 | 24.6 | 13.2% | 6/9 | safe | |
| Precision Medicine Platforms | $148.86B | 37.2 | 5.9 | 22.3 | 7.6% | 6/9 | safe | |
| AI-Powered Analytics & Decision Systems | $120.65B | — | 22.2 | -123.2 | −50.7% | 4/9 | safe | |
| AI-Powered Analytics & Decision Systems | $99.27B | 559.0 | 25.0 | 655.9 | 4.1% | 6/9 | safe | |
| AI-Powered Analytics & Decision Systems | $94.14B | 21.4 | 13.8 | 17.4 | 139.4% | 8/9 | safe |
Figures describe Caris Life Sciences shares, not any token. From theme classifications, Massive's related companies and the latest ratios and scores. Ratios are trailing, each as of its own latest filing. Peers are for comparison, not a list of alternatives to buy.